Desonide is a prescription topical treatment for redness, swelling, itching, and discomfort of various skin conditions.

[3] Pharmacists and prescribing physicians should be aware that this medication may contain inactive ingredients than can cause allergic reactions.

After stopping treatment, reversible hypothalamic-pituitary-adrenal (HPA) axis suppression with the potential for glucocorticosteroid insufficiency is possible.

Common medications causing a minor negative drug interaction include: Insulin and Metformin.

Other suppliers for the generic desonide include Rebel Distributors Corp and Perrigo New York Inc. Desonate was approved by the FDA following two major clinical trials in 2006.

Each randomized, double-blind, placebo-controlled study enrolled 582 pediatric patients (between the ages of 3 months and 18 years).

In clinical trial 1, 44% of patients succeeded successful treatment of Desonate versus 14% treated with the placebo.

In clinical trial 2, 28% of patients succeeded successful treatment of Desonate versus 6% treated with the placebo.

The randomized, double-blind, active control, 5-week study compared the effects of treatment of both creams through twice-a-day application.

The clinical trial is sponsored by NeoStrata Company, Inc.[citation needed] No research has been completed to evaluate the carcinogenic or photoco-carcinogenic potential of desonide.

The patent defends the suitability of the anti-inflammatory for the treatment of cutaneous disorders or disruptions characterized by skin inflammation and/or hyperproliferative activity in the epidermis.